View Older Stories View More Recent Stories

Feb 22, 2024 11:45AM OmniGuide(TM) Holdings and UROTECH (Medi-Globe Group Subsidiary) Announce Partnership to Expand Global Urology Patient Therapies
Feb 21, 2024 04:13PM Form SC 13D/A Kinnate Biopharma Inc. Filed by: ORBIMED ADVISORS LLC
Feb 14, 2024 07:45PM Form SC 13G/A ALX ONCOLOGY HOLDINGS Filed by: ORBIMED ADVISORS LLC
Feb 14, 2024 07:41PM Form SC 13G InspireMD, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 14, 2024 07:37PM Form SC 13G/A X4 Pharmaceuticals, Inc Filed by: ORBIMED ADVISORS LLC
Feb 14, 2024 07:32PM Form SC 13G/A Verastem, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 14, 2024 07:29PM Form SC 13G/A SI-BONE, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 14, 2024 07:22PM Form SC 13G Scholar Rock Holding Filed by: ORBIMED ADVISORS LLC
Feb 14, 2024 07:12PM Form SC 13G/A Protara Therapeutics, Filed by: ORBIMED ADVISORS LLC
Feb 14, 2024 07:00PM Form SC 13G/A NeuroPace Inc Filed by: ORBIMED ADVISORS LLC
Feb 14, 2024 06:56PM Form SC 13G/A Mersana Therapeutics, Filed by: ORBIMED ADVISORS LLC
Feb 14, 2024 06:51PM Form SC 13G/A Mereo BioPharma Group Filed by: ORBIMED ADVISORS LLC
Feb 14, 2024 06:48PM Form SC 13G/A Kezar Life Sciences, Filed by: ORBIMED ADVISORS LLC
Feb 14, 2024 06:43PM Form SC 13G Elevation Oncology, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 14, 2024 06:36PM Form SC 13G/A Crinetics Pharmaceutical Filed by: ORBIMED ADVISORS LLC
Feb 14, 2024 06:31PM Form SC 13G/A Applied Therapeutics Filed by: ORBIMED ADVISORS LLC
Feb 14, 2024 04:14PM Form 13F-HR ORBIMED ADVISORS LLC For: Dec 31
Feb 13, 2024 08:00AM BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics
Feb 12, 2024 11:08AM TRAWSFYNYDD THERAPEUTICS RECEIVES APPROVAL FOR THE FIRST PATIENT TRIAL OF TRX01, A ONCE-DAILY PROTEASE INHIBITOR FOR THE TREATMENT OF COVID 19
Feb 7, 2024 06:00AM Scion Life Sciences Launches with Oversubscribed $310 Million Fund to Create and Build Exceptional Biotech Companies
Feb 5, 2024 04:49PM Form SC 13D/A CalciMedica, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 5, 2024 04:42PM Form SC 13D ArriVent Biopharma, Inc. Filed by: ORBIMED ADVISORS LLC
Jan 29, 2024 04:56PM Form SC 13D/A Adicet Bio, Inc. Filed by: ORBIMED ADVISORS LLC
Jan 25, 2024 08:41PM Form 3 ArriVent Biopharma, Inc. For: Jan 25 Filed by: ORBIMED ADVISORS LLC
Jan 25, 2024 04:26PM Form SC 13D/A Edgewise Therapeutics, Filed by: ORBIMED ADVISORS LLC
Jan 8, 2024 06:41AM Domain Therapeutics Strengthens Leadership Team to Spearhead Global Development and North American Expansion as the Leading GPCR Immuno-Oncology Company
Dec 29, 2023 04:16PM Form SC 13D/A ALPINE IMMUNE SCIENCES, Filed by: ORBIMED ADVISORS LLC
Dec 27, 2023 05:03PM Form 144 ALPINE IMMUNE SCIENCES, Filed by: ORBIMED ADVISORS LLC
Dec 27, 2023 05:01PM Form 144 ALPINE IMMUNE SCIENCES, Filed by: ORBIMED ADVISORS LLC
Dec 27, 2023 04:43PM Form SC 13D/A Theseus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Dec 15, 2023 06:18PM Form 144/A Disc Medicine, Inc. Filed by: ORBIMED ADVISORS LLC
Dec 15, 2023 06:15PM Form 144/A Disc Medicine, Inc. Filed by: ORBIMED ADVISORS LLC
Dec 15, 2023 06:12PM Form 144/A Disc Medicine, Inc. Filed by: ORBIMED ADVISORS LLC
Dec 15, 2023 04:49PM Form SC 13D/A Disc Medicine, Inc. Filed by: ORBIMED ADVISORS LLC
Dec 13, 2023 05:20PM Form SC 13D/A Keros Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
Dec 12, 2023 05:59PM Form 144 Disc Medicine, Inc. Filed by: ORBIMED ADVISORS LLC
Dec 12, 2023 05:53PM Form 144 Disc Medicine, Inc. Filed by: ORBIMED ADVISORS LLC
Dec 12, 2023 05:42PM Form 144 Disc Medicine, Inc. Filed by: ORBIMED ADVISORS LLC
Dec 6, 2023 04:44PM Form SC 13D/A SpringWorks Therapeutics Filed by: ORBIMED ADVISORS LLC
Dec 4, 2023 03:46PM Brenig Therapeutics Unveils Superior Safety Profile of LRRK2 Inhibitor BT-0267 with Exceptional CSF/Plasma Ratio at Future of Parkinson's Disease Conference
Nov 29, 2023 04:21PM Form SC 13D/A Apollomics Inc. Filed by: ORBIMED ADVISORS LLC
Nov 27, 2023 05:29PM Form 144 Apollomics Inc. Filed by: OrbiMed Advisors II Ltd
Nov 27, 2023 06:30AM Theseus Pharmaceuticals (THRX) Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital and OrbiMed Advisors; Unsolicited Proposal from Concentra Biosciences
Nov 27, 2023 06:30AM Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC
Nov 24, 2023 04:28PM Form SC 13D/A Theseus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Nov 22, 2023 04:07PM Form 144 PMV Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Nov 20, 2023 04:22PM Form SC 13D/A Apollomics Inc. Filed by: ORBIMED ADVISORS LLC
Nov 17, 2023 08:28AM Form SC 13D/A Kinnate Biopharma Inc. Filed by: ORBIMED ADVISORS LLC
Nov 16, 2023 04:34PM Form 144 Apollomics Inc. Filed by: OrbiMed Advisors II Ltd
Nov 14, 2023 08:53PM Form SC 13D/A Kinnate Biopharma Inc. Filed by: ORBIMED ADVISORS LLC
View More Recent Stories View Older Stories